BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36843580)

  • 21. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
    Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Random Forest for Predicting Treatment Response to Radioiodine and Thyrotropin Suppression Therapy in Patients With Differentiated Thyroid Cancer But Without Structural Disease.
    Sa R; Yang T; Zhang Z; Guan F
    Oncologist; 2024 Jan; 29(1):e68-e80. PubMed ID: 37669005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
    Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
    Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma.
    Wang C; Zhang R; Wang R; Meng Z; Zhang G; Dong F; He Y; Tan J
    Front Endocrinol (Lausanne); 2021; 12():667544. PubMed ID: 34040584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
    Pan M; Li Z; Jia M; Lu X
    Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
    Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
    Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
    [No Abstract]   [Full Text] [Related]  

  • 27. The Value of Stimulated Thyroglobulin Before the First Radioactive Iodine Treatment in Metastasis for Differentiated Thyroid Carcinoma.
    Ren L; Zhang C; Shen Y; Mo A; Hu Y; Sun J; Yuan C; Wen W
    Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107643
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
    Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
    Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
    Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
    Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
    Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
    [No Abstract]   [Full Text] [Related]  

  • 34. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study.
    Liu Y; Wang Y; Zhang W
    EJNMMI Res; 2022 Jul; 12(1):45. PubMed ID: 35904608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
    Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
    Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 38. Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis.
    Parvathareddy SK; Siraj AK; Siraj N; Ahmed SO; Al-Rasheed M; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Front Endocrinol (Lausanne); 2024; 15():1326976. PubMed ID: 38812819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
    Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
    Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.